Literature DB >> 1318222

Resistance of in vivo-selected spontaneously transformed cells and Rous sarcoma virus-transformed cells to macrophage-mediated cytotoxicity.

E A Volpe1.   

Abstract

The cytotoxic activity (CTA) of activated peritoneal macrophages (MP) on variant lines of Syrian hamster embryo (HE) cells of differing malignant characteristics was studied. The target cells were a line of low-malignant cells resulting from spontaneous transformation of HE cells in vitro (STHE strain), and malignant variants selected from them in vivo (STHE-LM-4, STHE-LM-8, and STHE-75/18 strains). In addition, we used cells of the HET-SR-1 strain; these are HE cells transformed in vitro by a tumorigenic Rous sarcoma virus (Schmidt-Ruppin strain, RSV-SR), or the TU-SR strain induced by RSV-SR in vivo. Thioglycollate-elicited peritoneal MP from Syrian hamsters were activated in vitro with bacterial levan, LPS or MDP and used as effector cells. MP-mediated cytolysis was determined by means of a 42-h radioactivity release assay with 3H-thymidine-labeled target cells. We found that only the parental STHE cells were susceptible towards fully-activated MP-mediated CTA. All three of the in vivo-selected malignant variants of the STHE cell sublines, as well as the tumorigenic RSV-SR transformants, were resistant to cytolysis by activated MP. Non-activated thioglycollate-elicited MP did not lyse any of the tumor cells studied.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1318222     DOI: 10.1007/bf01928174

Source DB:  PubMed          Journal:  Experientia        ISSN: 0014-4754


  22 in total

1.  Clustering of discrete cell properties essential for tumorigenicity and metastasis. II. Studies of Syrian hamster embryo fibroblasts transformed by Rous sarcoma virus.

Authors:  G I Deichman; H A Kashleva; T E Kluchareva; V A Matveeva
Journal:  Int J Cancer       Date:  1989-11-15       Impact factor: 7.396

2.  Clustering of discrete cell properties essential for tumorigenicity and metastasis. I. Studies of Syrian hamster embryo fibroblasts spontaneously transformed in vitro.

Authors:  G I Deichman; T E Kluchareva; V A Matveeva; N E Kushlinsky; L S Bassalyk; E L Vendrov
Journal:  Int J Cancer       Date:  1989-11-15       Impact factor: 7.396

3.  Differential sensitivity of metastatic versus nonmetastatic mammary tumor cells to macrophage-mediated cytostasis.

Authors:  K Yamashina; A Fulton; G Heppner
Journal:  J Natl Cancer Inst       Date:  1985-10       Impact factor: 13.506

Review 4.  Secretory products of macrophages.

Authors:  C F Nathan
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

5.  Heterogeneity of murine mammary adenocarcinoma cell subpopulations. In vitro and in vivo resistance to macrophage cytotoxicity and its association with metastatic capacity.

Authors:  Y Yamamura; B C Fischer; J B Harnaha; J W Proctor
Journal:  Int J Cancer       Date:  1984-01-15       Impact factor: 7.396

6.  Augmentation of metastasis formation by thioglycollate-elicited macrophages.

Authors:  E Gorelik; R H Wiltrout; M J Brunda; H T Holden; R B Herberman
Journal:  Int J Cancer       Date:  1982-05-15       Impact factor: 7.396

7.  Stepwise immunologic selection of antigenic variants during tumor growth.

Authors:  J L Urban; M L Kripke; H Schreiber
Journal:  J Immunol       Date:  1986-11-01       Impact factor: 5.422

8.  Tumor necrosis factor: a potent effector molecule for tumor cell killing by activated macrophages.

Authors:  J L Urban; H M Shepard; J L Rothstein; B J Sugarman; H Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

9.  Differences in cytotoxic effects of activated murine peritoneal macrophages and J774 monocytic cells on metastatic variants of B16 melanoma.

Authors:  K M Miner; J Klostergaard; G A Granger; G L Nicolson
Journal:  J Natl Cancer Inst       Date:  1983-04       Impact factor: 13.506

Review 10.  Natural host resistance and in vivo selection of malignant tumour cells.

Authors:  G I Deichman
Journal:  Cancer Surv       Date:  1988
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.